Astellas Pharma Inc.

$13.15 USD

$0.3 (2.33%)

Volume: 990
Average Volume: 4.01K
Market Capitalization: $23.56B
P/E Ratio: 13.20
Dividend Yield: 3.63%
Price Target

Year High: $17.85
Year Low: $9.34
Day High: —
Day Low: —
Payout Ratio: $0.47
Current Ratio: $1.17

Industry, Sector & symbol

Stock Exchange	OTC
CEO	Naoki Okamura
Industry	Drug Manufacturers - General
Sector	Healthcare
Current Symbol	ALPMF
CUSIP	None
CIK	None
Web	https://www.astellas.com
Phone	81 3 3244 3000
Currency	USD
Employees	14099
Country	JP

Liquidity

Debt-to-Equity Ratio	0.31
Payout Ratio	0.47
Current Ratio	1.17
Quick Ratio	0.90
Cash Ratio	0.23

Sales & Book Value

Annual Sales	$2.15T
Price / Sales	1.80
Cash Flow	283.18
Price / Cash Flow	7.57
Price / Book	2.11

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecast Upside/Downside	%
Consensus Rating	Buy
Rating Score(0-5)	4
Research Coverage	0 Analysts

Profitability

EPS (Most Recent Fiscal Year)	$162.98
Trailing P/E Ratio	13.20
PEG Ratio	0.03
P/E Growth	0.03
Net Income	$293.37B
Net Margin	13.63%
Pretax Margin	17.60%
Return on Equity	17.44%
Return on Assets	8.17%

Financials Score

AltmanZ Score	2.70
Piotroski Score	8.00
Working Capital	204.8B
Total Assets	3.59T
Ebit	427.35B
Market Cap	3.73T
Total Liabilities	1.75T

Poll Results

About Astellas Pharma Inc. (OTC:ALPMF) Stock

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, encompassing the development, manufacturing, distribution, and commercialization of medicinal products across international markets. Its diverse portfolio features prominent therapies such as XTANDI, an androgen receptor signaling inhibitor for prostate cancer, and XOSPATA, an FLT3 inhibitor targeting relapsed or refractory acute myeloid leukemia in adult patients with a specific FLT3 mutation. Other key offerings include PADCEV, designed for locally advanced or metastatic urothelial cancer, and the Betanis/Myrbetriq/BETMIGA family of beta-3 adrenergic receptor agonists used to alleviate symptoms of overactive bladder, including urgency, frequent urination, and urge incontinence. The company also markets Evrenzo, an oral ... medication for anemia linked to chronic kidney disease, and the immunosuppressants Prograf and Advagraf/Graceptor/ASTAGRAF, critical for preventing organ rejection post-transplantation. Further contributions to its product range include mirabegron for neurogenic detrusor overactivity in children, Vesicare for general overactive bladder treatment, Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, and the antifungal agent Funguard/MYCAMINE. Astellas is actively engaged in numerous strategic alliances and collaborations to advance its research and development initiatives. These include clinical trial partnerships with Merck & Co., Inc. and CytomX Therapeutics, Inc., as well as an agreement with BANDAI NAMCO Entertainment Inc. for a smartphone-based exercise support application. The company maintains a strategic research alliance with Harvard University, focusing on the co-development of novel therapeutics and technologies. Additionally, it has a research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies utilizing Actinium's Antibody Warhead Enabling technology platform, and an agreement with Zenith Epigenetics Ltd. to assess ZEN-3694. A collaboration agreement is also in place with Cytokinetics, Incorporated. Furthermore, Astellas has a strategic collaboration and licensing deal with Minovia Therapeutics Ltd. aimed at the research, development, and commercialization of cell therapy programs addressing diseases stemming from mitochondrial dysfunction. Established in 1923, Astellas Pharma Inc. has its corporate headquarters situated in Tokyo, Japan.

Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript

2026-04-28 00:31:36

Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Astellas Pharma Inc. (ALPMF) stock price?: Astellas Pharma Inc.(OTC:ALPMF) stock price is $13.15 in the last trading session. During the trading session, ALPMF stock reached the peak price of $17.85 while $9.34 was the lowest point it dropped to. The percentage change in ALPMF stock occurred in the recent session was 2.33% while the dollar amount for the price change in ALPMF stock was $0.3.
ALPMF's industry and sector of operation?: The OTC listed ALPMF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
Who are the executives of ALPMF?: Jun Kono | Senior Executive Officer & Head of Japan Commercial
Nobuko Kato | Chief Communications & Investor Relations Officer
Nori Kuwahara | Senior Vice President of Planning & Administration
Yoshitsugu Shitaka | Chief Scientific Officer & Senior Managing Executive Officer
Atsushi Kitamura | Chief Financial Officer
How many employees does ALPMF have?: Number of ALPMF employees currently stands at 14099. ALPMF operates from 2-5-1, Nihonbashi-Honcho, Tokyo, TY 103-8411, JP.

Link for ALPMF official website?: Official Website of ALPMF is: https://www.astellas.com
How do I contact ALPMF?: ALPMF could be contacted at phone #81 3 3244 3000 and can also be accessed through its website. ALPMF operates from 2-5-1, Nihonbashi-Honcho, Tokyo, TY 103-8411, JP.
How many shares of ALPMF are traded daily?: The average number of ALPMF shares traded daily for last 3 months was 4.01K.
What is the market cap of ALPMF currently?: The market value of ALPMF currently stands at $23.56B with its latest stock price at $13.15